The immune system carries enormous responsibility. It must recognize an almost unlimited number of potential threats. These foreign molecules, known as antigens, can come from pathogens or cancerous cells. When confronted with danger, the adaptive immune system relies on T cells equipped with highly specific receptors. Understanding which part of an antigen is recognized by a given T cell receptor (TCR) is key to decoding immune responses in diseases such as cancer. ImmuneWatch, based in Antwerp, Belgium, is focused on solving one of the longest-standing challenges in systems immunology: Predicting T cell specificity using machine learning.
“ImmuneWatch DETECT is the perfect add on to make the QIAseq-derived TCR data more insightful. You can use ImmuneWatch DETECT to extract the maximum amount of value out of your T cell repertoire.”
Sander Wuyts, Ph.D., CEO and cofounder of ImmuneWatch
Sander Wuyts, Ph.D., CEO and cofounder of ImmuneWatch
Sander Wuyts is the CEO and cofounder of ImmuneWatch, a spinoff of the University of Antwerp and Antwerp University Hospital in Belgium. With a background in Bioscience engineering with a strong focus on bioinformatics and multi-omics analysis, Sander is now driving ImmuneWatch’s core mission of annotating the specificity of each T cell receptor in a T cell receptor repertoire, driving advances in immuno-monitoring in oncology and vaccine development.
March 2026